Download Progress In Neurotherapeutics And Neuropsychopharmacology Volume 2 2007 full books in PDF, epub, and Kindle. Read online free Progress In Neurotherapeutics And Neuropsychopharmacology Volume 2 2007 ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Jeffrey L. Cummings |
| Publisher | : Cambridge University Press |
| Total Pages | : 298 |
| Release | : 2007-04-12 |
| Genre | : Medical |
| ISBN | : 9780521862547 |
An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders.
| Author | : Jeffrey L. Cummings |
| Publisher | : Cambridge University Press |
| Total Pages | : 314 |
| Release | : 2008-03-06 |
| Genre | : Medical |
| ISBN | : 0521862558 |
An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders.
| Author | : Jeffrey L. Cummings |
| Publisher | : Cambridge University Press |
| Total Pages | : 0 |
| Release | : 2012-07-26 |
| Genre | : Psychology |
| ISBN | : 9781107405806 |
Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.
| Author | : Jonathan K. Okinaga |
| Publisher | : Wipf and Stock Publishers |
| Total Pages | : 159 |
| Release | : 2022-09-23 |
| Genre | : Religion |
| ISBN | : 1666706493 |
Since Benjamin Rush first introduced the disease of wills as the cause of alcoholism, a steady and slow infiltration of the disease model has infected how the church treats those who struggle with addictions. The first organization that truly sought to remove the soul care of addicts from the church was Alcoholics Anonymous (AA), through their bestselling The Big Book of AA and the introduction of the 12 Steps. AA’s influence on how the church confronts addiction still reverberates today, with many of the ministries that address addiction firmly rooted in what can be found in AA literature. Addictions were once viewed as an issue caused by sin and best addressed through faith and prayer. Currently addiction is seen through the lens of disease. The ramifications are consequential as more church members are struggling with addictions than ever before. Tracing the progression of addiction from sin to disease will reveal that the SBC and its churches have been negligent in understanding the underlying foundations of AA and the influence that the medicalization of substance abuse has had on how churches approach what should be classified as a sin issue.
| Author | : Eric S. Hsu |
| Publisher | : Cambridge University Press |
| Total Pages | : 398 |
| Release | : 2013-10-24 |
| Genre | : Medical |
| ISBN | : 1107513448 |
Pain management is an essential part of clinical practice for all healthcare providers from trainees, physician assistants and nurse practitioners through to practising physicians. Problem-Based Pain Management is a collaboration between experts in anesthesiology, geriatric medicine, neurology, psychiatry and rehabilitation which presents a multidisciplinary management strategy. Over 60 chapters follow a standard, easy-to-read, quick access format on: clinical presentation, signs and symptoms, lab tests, imaging studies, differential diagnosis, pharmacotherapy, non-pharmacologic approach, interventional procedure, follow-up and prognosis. The broad spectrum of topics include headache, neck and back pain, bursitis, phantom limb pain, sickle cell disease and palliative care. Unlike other large, cumbersome texts currently available, this book serves as a quick, concise and pertinent reference in the diagnosis and management of common pain syndromes.
| Author | : Theodore A. Stern |
| Publisher | : Elsevier Health Sciences |
| Total Pages | : 329 |
| Release | : 2015-04-27 |
| Genre | : Medical |
| ISBN | : 0323413234 |
Put today's best approaches to work for your patients with this practical guide to cutting-edge psychopharmacologic and somatic treatments for psychiatric and neurologic conditions. Comprised of key chapters from the second edition of Stern et al.'s Massachusetts General Hospital Comprehensive Clinical Psychiatry, this user-friendly resource focuses on current psychotropic treatments, electroconvulsive therapy, and neurotherapeutics, making it an ideal quick reference for psychiatrists, psychologists, internists, and nurse practitioners. - Stay current with hot topics in the field, including the use of antiepileptic drugs in psychiatry, ADHD medications, and often-overlooked areas such as treatment of pain. - Benefit from the authoritative content of the parent text, MGH Comprehensive Clinical Psychiatry, 2nd Edition, now featuring new art, new tables, and key points, and updated to DSM-5 where relevant. - Get detailed coverage of antidepressants, antipsychotics, and antianxiety medications, as well as drug interactions, side effects, and treatment adherence. - Quickly find the information you need with a user-friendly, highly templated format that features abundant boxed summaries, bulleted points, case histories, algorithms, references, and suggested readings. - Test your knowledge of psychopharmacology and neurotherapeutics with interactive, downloadable multiple-choice questions with detailed answers for each chapter.
| Author | : S. Nassir Ghaemi |
| Publisher | : CRC Press |
| Total Pages | : 363 |
| Release | : 2002-05-06 |
| Genre | : Medical |
| ISBN | : 020390902X |
This practical reference examines the advantages and disadvantages of polypharmacy in psychiatry, and provides up-to-date clinical guidelines on the appropriate use of combinations of pharmacological therapy in major psychiatric disorders-including multidisciplinary approaches to treatment, such as social work and psychopharmacology, and an examina
| Author | : |
| Publisher | : Academic Press |
| Total Pages | : 404 |
| Release | : 2020-06-29 |
| Genre | : Medical |
| ISBN | : 0128201908 |
The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 483 |
| Release | : 2017-09-28 |
| Genre | : Medical |
| ISBN | : 0309459575 |
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
